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vascular stenosis with DEB is associated with signiﬁcantly lower risk
of TLR at both 12 and 24 months. DEB use is also associated with 64%
higher patency rates compared to BA. Further studies are necessary
assess the beneﬁts of mortality with the use of DEB for peripheral
vascular interventions.
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BACKGROUND Implantation of a transcatheter valve into a degen-
erated surgical bioprosthesis during aortic valve-in-valve (ViV) pro-
cedure may signiﬁcantly reduce the effective oriﬁce area (EOA)
available for blood ﬂow. We sought to investigate the impact of
prosthesis-patient mismatch (PPM) on hemodynamics and survival in
these patients.
METHODS A total of 657 data sets of aortic ViV procedures from the
Valve-in-Valve International Data Registry were investigated for the
current analysis. Severe PPM after ViV procedure was deﬁned as an
indexed EOA < 0.65cm2/m2 patient body surface area (BSA).
RESULTS Severe PPM was present in 202 patients after aortic ViV
implantation (30.7% total, 61.4% men, STS score 10.6%). Theincidence of severe PPM was higher in patients who received a
balloon-expandable device than a self-expandable device (38.4% vs.
21.5%, p<0.0001). Patients with severe PPM were younger (77.2  9.4
years vs. 78.7  8.1, p ¼ 0.05) and had larger body weight (80.9  18.9
kg vs. 72.6  14.1, p<0.0001) than those without severe PPM. In
addition, patients with severe PPM had higher aortic mean gradient
after the procedure (21.6  10 mmHg vs. 14.1  7.4) and lower aortic
valve area (1.03  0.2 cm2 vs. 1.66  0.44), in comparison with pa-
tients without severe PPM. Multivariate analysis revealed indepen-
dent predictors for having severe PPM after aortic ViV: effective
oriﬁce area before the procedure (Odds Ratio, OR 0.53 per 1cm2,
conﬁdence interval, CI, 0.3-0.94, p¼0.03), patient age (OR, 0.97 per
1year increment, CI, 0.94-0.99, p¼0.01), using a balloon expandable
device (OR, 2.82, CI, 1.78-4.46, p<0.001). In patients who survived
aortic ViV implantation procedure, one-year survival was not affected
by having severe PPM (93.3% vs. 93.8% in patients without severe
PPM, log rank p¼0.9).
CONCLUSIONS Severe PPM is common after aortic ViV implantation,
occurring in approximately one-third of patients. Predictors for severe
PPM include young age, stenotic surgical valves and balloon-
expandable device implantation. Despite higher valve gradients in
patients with severe PPM, one-year survival was similar to those
without severe PPM. Therefore, the risk of severe PPM should not
discourage operators from performing ViV procedures in inoperable
elderly patients.
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BACKGROUND Cardiac troponin-I (cTnI) is a marker of myocardial
injury and improvements in assay sensitivity allow precise quantiﬁ-
cation at extremely low serum concentrations. Increased cTnI con-
centrations are known to predict outcomes in patients with stable
coronary artery disease, although the underlying mechanisms remain
unknown. As rupture of thin-cap ﬁbroatheroma (TCFA) is thought
responsible for the majority of myocardial infarctions, we tested the
association between baseline cTnI concentration and plaque
classiﬁcation.
METHODS Patients undergoing planned percutaneous coronary
intervention (PCI) for stable angina pectoris (n¼99) underwent 3-
vessel virtual-histology intravascular ultrasound imaging (VH-IVUS,
Eagle-Eye Gold, Volcano Corp) before intervention. Virtual-histology
(VH)-TCFA were deﬁned as plaques (plaque burden >40%) with >10%
necrotic core in contact with lumen for 3 consecutive frames. High-
sensitivity cTnI was taken before PCI (ARCHITECT STAT high-sensi-
tivity cTnI assay, Abbott Laboratories, Abbott Park, Il, USA), with
patients subsequently stratiﬁed into tertiles. Major adverse cardio-
vascular events (MACE) were determined at follow-up (median 1,115
days).
RESULTS Serum cTnI concentrations for each tertile were; low 2.0
[2.0-3.0]ng/L, intermediate 4.0 [4.0-5.0]ng/L and high 7.0 [6.0-18.0]
ng/L. In comparison with the lowest cTnI tertile, highest tertile pa-
tients were older (679.7 vs. 59.810.6yrs, p¼0.002). However, there
were no other differences in demographics between these groups,
including diabetes mellitus (14.8 vs. 12.0%, p¼0.98), hypertension
(55.6 vs. 44.0%, p¼0.33) and serum creatinine (1.000.15 vs.
0.970.21mg/dL, p¼0.37). On 3-vessel VH-IVUS, total plaque number
(p¼0.27), plaque volume (p¼0.09), % necrotic core (p¼0.17) and %
calciﬁcation (p¼0.21) were similar between lowest and highest ter-
tiles. However, patients in the highest cTnI tertile had a higher
number of VH-TCFA, when compared with lowest tertile (2.0 [1.0-2.8]
vs. 1.0 [0.0-1.3], p¼0.027). On multivariable linear regression analysis,
cTnI concentration (p¼0.01) was independently associated with
